|IACP Member Alert: FDA Addresses Questions for the Record (QFR)|
The Food & Drug Administration (FDA) has sent their responses to the Questions for the Record submitted by U.S. Representative Morgan Griffith (R-VA). IACP's questions regarding Office Use are included on pages 41-43.
In a September 15th letter to Representatives Griffith, Green and DeGette, the Food & Drug Administration (FDA) clearly stated it is interpreting 503A to only permit the compounding of prescriptions for individual patients. This is in direct contradiction to Congressional intent as included in several "Statements of the Record" from Senators and Congressmen that nothing in the Drug Quality & Security Act was intended to interfere with state authority over the practice of pharmacy.
Capitol Connections member newsletter, distributing Friday, September 19th, for more information.
Tell us how compounded pharmaceuticals have helped you, someone you know, or how you have helped someone as a practicing compounding pharmacist. Help us protect your continued access to pharmacy compounding!
Share the P3 community and the value and necessity of personalized prescriptions with your friends.